Galor Anat, Ference Sandra J, Singh Arun D, Lee Michael S, Stevens Glen H J, Perez Victor L, Peereboom David M
Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
Am J Ophthalmol. 2007 Jul;144(1):45-49. doi: 10.1016/j.ajo.2007.03.057.
To report on the development of visually significant maculopathy associated with blood-brain barrier disruption (BBBD) therapy for the treatment of central nervous system (CNS) lymphoma.
Retrospective case series.
Chart review of 20 patients undergoing BBBD therapy for treatment of CNS lymphoma at the Cleveland Clinic. Patients with documented maculopathy were included in analysis.
Seven (54%) of 13 patients were identified with new macular retinal pigment epithelium (RPE) changes after BBBD treatment. The RPE changes consisted of fine clumps of hyperpigmentation in the foveal region associated with variable degrees of RPE loss. These changes were bilateral but often asymmetric. Two patients had decreased visual acuity resulting from maculopathy. One patient had documented progression of maculopathy after completion of treatment.
Maculopathy is a frequent finding after BBBD therapy for CNS lymphoma.
报告与血脑屏障破坏（BBBD）疗法治疗中枢神经系统（CNS）淋巴瘤相关的具有视觉意义的黄斑病变的发生情况。
回顾性病例系列。
对克利夫兰诊所接受BBBD疗法治疗CNS淋巴瘤的20例患者进行病历审查。纳入有记录的黄斑病变患者进行分析。
13例患者中有7例（54%）在BBBD治疗后出现新的黄斑视网膜色素上皮（RPE）改变。RPE改变表现为黄斑区细小的色素沉着团块，伴有不同程度的RPE丧失。这些改变为双侧性，但通常不对称。两名患者因黄斑病变导致视力下降。一名患者在治疗完成后有记录的黄斑病变进展。
黄斑病变是BBBD疗法治疗CNS淋巴瘤后常见的发现。
